Clinical trial number NCT00394914 for "Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295AM2)" at ClinicalTrials.gov
Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA (January 2009). "New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3". Antiviral Research. 81 (1): 56–63. doi:10.1016/J.ANTIVIRAL.2008.09.002. PMID18840470.
Ledford RM, Collett MS, Pevear DC (December 2005). "Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril". Antiviral Research. 68 (3): 135–138. doi:10.1016/j.antiviral.2005.08.003. PMID16199099.
Braun H, Makarov VA, Riabova OB, Wutzler P, Schmidtke M (2011). "Amino Acid Substitutions At Residue 207 of Viral Capsid Protein 1 (VP1) Confer Pleconaril Resistance in Coxsackievirus B3 (CVB3)". Antiviral Research. 90 (2): A54 –A55. doi:10.1016/j.antiviral.2011.03.100.
Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA (January 2009). "New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3". Antiviral Research. 81 (1): 56–63. doi:10.1016/j.antiviral.2008.09.002. PMID18840470.
Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA (January 2009). "New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3". Antiviral Research. 81 (1): 56–63. doi:10.1016/J.ANTIVIRAL.2008.09.002. PMID18840470.
Ledford RM, Collett MS, Pevear DC (December 2005). "Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril". Antiviral Research. 68 (3): 135–138. doi:10.1016/j.antiviral.2005.08.003. PMID16199099.
Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA (January 2009). "New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3". Antiviral Research. 81 (1): 56–63. doi:10.1016/j.antiviral.2008.09.002. PMID18840470.